You are here

Phase II Trial of MSCs in BPD

Previous research had demonstrated the safety and feasibility of mesenchymal stem cell (MSC) transplantation for bronchopulmonary dysplasia (BPD) treatment in preterm infants in a phase I clinical trial. Now, researchers led by Won Soon Park (Sungkyunkwan University School of Medicine) and Ai‐Rhan Kim (University of Ulsan College of Medicine, Seoul, South Korea) report on a phase II double‐blind, randomized, placebo‐controlled clinical trial conducted in preterm infants with BPD receiving mechanical ventilator support with respiratory deterioration. Overall, the results reported in this new STEM CELLS Translational Medicine study support the safety and feasibility of MSC therapy.